All In Biotech

Drug Trial Radar · NCT04114539

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects With Tourette's Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

124

Actual

Start

Oct 4, 2019

Primary completion

Nov 11, 2022

Study completion Nov 11, 2022

Sponsor

Lead sponsor
Emalex Biosciences Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.

Conditions

  • Tourette Syndrome in Children
  • Tourette Syndrome in Adolescence

Interventions

  • EcopipamDrug

    Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related)Time frame: From start of study drug administration until 30 days after last dose (Up to Month 13)
  2. Change From Baseline in Hematology Parameters: Basophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
  3. Change From Baseline in Hematology Parameters: Eosinophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
  4. Change From Baseline in Hematology Parameters: ErythrocytesTime frame: Baseline up to Month 12
  5. Change From Baseline in Hematology Parameters: HematocritTime frame: Baseline up to Month 12
  6. Change From Baseline in Hematology Parameters: HemoglobinTime frame: Baseline up to Month 12
  7. Change From Baseline in Hematology Parameters: Leukocytes and PlateletsTime frame: Baseline up to Month 12
  8. Change From Baseline in Hematology Parameters: Lymphocytes to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
  9. Change From Baseline in Hematology Parameters: Monocytes to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
  10. Change From Baseline in Hematology Parameters: Neutrophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
  11. Change From Baseline in Serum Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Lactase DehydrogenaseTime frame: Baseline up to Month 12
  12. Change From Baseline in Serum Chemistry Parameters: Albumin, Globulin and ProteinTime frame: Baseline up to Month 12
  13. Change From Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglyceride and Urea NitrogenTime frame: Baseline up to Month 12
  14. Change From Baseline in Serum Chemistry Parameters: Bilirubin, Creatinine and Direct BilirubinTime frame: Baseline up to Month 12
  15. Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline up to Month 12
  16. Change From Baseline in Vital Signs Parameter: Diastolic Blood Pressure and Systolic Blood PressureTime frame: Baseline up to Month 12
  17. Change From Baseline in Vital Signs Parameter: Pulse RateTime frame: Baseline up to Month 12
  18. Change From Baseline in Vital Signs Parameter: Body Mass Index [BMI]Time frame: Baseline up to Month 12
  19. Change From Baseline in Vital Signs Parameter: HeightTime frame: Baseline up to Month 12
  20. Change From Baseline in Vital Signs Parameter: WeightTime frame: Baseline up to Month 12
  21. Change From Baseline in Electrocardiogram (ECG) Values Parameters: Aggregate PR Interval, Aggregate QRS Duration, Aggregate QT Interval, and Aggregate QTc IntervalTime frame: Baseline to Month 12
  22. Number of Participants With Clinically Significant Abnormal Physical Examination FindingsTime frame: Baseline up to Month 12

Locations

65 sites in 5 countries. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Advanced Research Center Inc.

    Anaheim, California

  • UCLA

    Los Angeles, California

  • PCSD-Feighner Research

    San Diego, California

  • Syrentis Clinical Research

    Santa Ana, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Northwest Florida Clinical Research Group, LLC

    Gulf Breeze, Florida

  • Research in Miami Inc.

    Hialeah, Florida

  • University of Miami

    Miami, Florida

  • MedBio Trials

    North Miami, Florida

  • APG Research LLC

    Orlando, Florida

  • University of South Florida

    St. Petersburg, Florida

  • Pediatric Epilepsy and Neurology Specialists

    Tampa, Florida

  • Pediatric Neurology, PA

    Winter Park, Florida

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Meridian Clinical Research

    Savannah, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • The University of Chicago Hospitals

    Chicago, Illinois

  • AMR - Baber Research Inc.

    Naperville, Illinois

  • Psychiatric Associates

    Overland Park, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Michigan Clinical Research Institute PC

    Ann Arbor, Michigan

  • Neurobehavioral Medicine Group

    Bloomfield Hills, Michigan

  • Helen DeVos Children's Hospital / Spectrum Health Medical Group

    Wyoming, Michigan

  • St. Charles Psychiatric Associates dba Midwest Research Group

    Saint Charles, Missouri

  • Movement Disorders Center

    St Louis, Missouri

  • Alivation Research, LLC

    Lincoln, Nebraska

  • Center for Psychiatry and Behavioral Medicine Inc.

    Las Vegas, Nevada

  • The NeuroCognitive Institute

    Mount Arlington, New Jersey

  • Clinical Research Center of NJ

    Voorhees Township, New Jersey

  • New York Neurology Associates P.C

    New York, New York

  • Hapworth Research Inc.

    New York, New York

  • Mount Sinai School of Medicine

    New York, New York

  • Mood Disorders Consulting Medicine PLLC

    New York, New York

  • Finger Lakes Clinical Research

    Rochester, New York

  • Quest Therapeutics of Avon Lake

    Avon Lake, Ohio

  • Cincinnati Childrens Hospital Medical Center

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.